BHST - Rasio utang marang kapitalisasi buku BioHarvest Sciences, Inc.

Logo grafis BioHarvest Sciences, Inc. (BHST)

The price evolution of BioHarvest Sciences (BHST) demonstrates the dynamics of an asset currently valued at 0.95. BioHarvest Sciences (BHST) dominates pricing through innovative Bio-Farming, creating pure plant cells without agrochemicals. Revenue is generated by supplying premium bioactive components for medicine and nutrition. The business's ecological focus relies on bioreactors, which radically reduce the consumption of water resources and land.

BHST (BioHarvest Sciences Inc) riwayat Utang marang nilai buku saka 13.11.2024 nganti 28.10.2026
Barang utama BioHarvest

This ratio assesses the stability of the capital structure by comparing total debt obligations against the book value of assets to determine the level of leverage. By analyzing the trend of the debt-to-equity ratio, an investor can observe the balance between financial stability and investments in scaling the bioreactor capacities of BioHarvest Sciences (BHST), which enable the production of pure nutrients independently of external climatic factors.

Pesaing BioHarvest Sciences

Utang-utang marang kapitalisasi buku HLN (Haleon plc)|kenvue.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Verona Pharma (VRNA)|MENS: Rasio utang marang aset resik|LGND (Ligand Pharma) - Rasio utang marang kapitalisasi buku|Amneal Corp (AMRX) - Utang marang nilai buku|PRGO (Perrigo Company plc) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku alvotech.com (ALVO)|Liquidia (LQDA) - Utang marang nilai buku|Rasio utang marang aset resik GLPG (Galapagos N.V.)|ANIP: Rasio utang marang kapitalisasi buku|MNKD - Utang-utang marang nilai buku|Utang marang nilai buku Amphastar Pharmaceuticals AMPH|PCRX - Utang marang modal buku|Utang-utang marang kapitalisasi buku ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku AQST (Aquestive Pharma)|Utang-utang marang nilai buku SCPH|Tectonic Therapeutic, Inc. (TECX) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik tonixpharma.com (TNXP)|Utang-utang marang kapitalisasi buku China SXT Pharmaceuticals, Inc. SXTC|Rasio utang marang kapitalisasi buku Eupraxia Pharmaceuticals, Inc. EPRX|Utang-utang marang kapitalisasi buku EXOZ (Invizyne Technologies, Inc.)|ORMP: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku ENTX|ipatherapeutics.com (HYFT) - Utang-utang marang nilai buku|ABVC - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik Cumberland Pharmaceuticals Inc|Utang-utang marang kapitalisasi buku QNTM|Utang-utang marang kapitalisasi buku FGEN (FibroGen Corporation)|Rasio utang marang kapitalisasi buku Telomir Pharmaceuticals|RANI - Rasio utang marang aset resik|SNYR - Utang marang nilai buku|RLYB - Rasio utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku LEXX|PULM (Pulmatrix Corporation) - Utang-utang marang nilai buku|PTHL: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik Aptorum (APM)|Utang marang nilai buku Lyra Therapeutics|Utang marang modal buku Impact BioMedical, Inc. IBO|Utang marang nilai buku TNF Pharmaceuticals, Inc.|cbdMD Inc. - Rasio utang marang aset resik|Rasio utang marang kapitalisasi buku PRFX (PainReform Ltd.)|CYTO - Utang-utang marang aset resik|LIPO (Lipella Pharmaceuticals, Inc.) - Utang-utang marang kapitalisasi buku|OptiNose Inc (OPTN) - Utang marang nilai buku|PIRS: Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik Procaps Group Corp|Petros Pharmaceuticals - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku QLI (qlsyy.net)|SLRN - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku TFF Pharmaceuticals Inc. TFFP